Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Minireviews
    • JVI Classic Spotlights
    • Archive
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About JVI
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Journal of Virology
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Minireviews
    • JVI Classic Spotlights
    • Archive
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About JVI
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Vaccines and Antiviral Agents

Recombinant Modified Vaccinia Virus Ankara Expressing the Surface gp120 of Simian Immunodeficiency Virus (SIV) Primes for a Rapid Neutralizing Antibody Response to SIV Infection in Macaques

Ilnour Ourmanov, Miroslawa Bilska, Vanessa M. Hirsch, David C. Montefiori
Ilnour Ourmanov
Laboratory of Molecular Microbiology, National Institutes of Allergy and Infectious Diseases, Rockville, Maryland 20852, and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Miroslawa Bilska
Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vanessa M. Hirsch
Laboratory of Molecular Microbiology, National Institutes of Allergy and Infectious Diseases, Rockville, Maryland 20852, and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David C. Montefiori
Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/JVI.74.6.2960-2965.2000
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • Fig. 1.
    • Open in new tab
    • Download powerpoint
    Fig. 1.

    Time course of SIVsmH-4-neutralizing antibody production following intravenous inoculation of vaccinated macaques with SIVsmE660. SIVsmH-4-neutralizing antibodies were measured in plasma samples obtained on the day of challenge and at multiple time points for 12 weeks postchallenge. Titers of neutralizing antibodies are the reciprocal plasma dilution at which 50% of CEMx174 cells were protected from virus-induced cell killing. Undetectable neutralization was given a value of 30, which was the lowest reciprocal plasma dilution tested. Panel A, MVA-gag-pol; panel B, MVA-env; panel C, MVA-gag-pol-env; panel D, MVA. †, animals sacrificed because of clinical manifestations of AIDS; ✞, animal that died of causes unrelated to AIDS.

  • Fig. 2.
    • Open in new tab
    • Download powerpoint
    Fig. 2.

    Time course of challenge-strain-neutralizing antibody production following intravenous inoculation of vaccinated macaques with SIVsmE660. SIVsmE660-neutralizing antibodies were measured in plasma samples obtained on the day of challenge and at multiple time points for 28 weeks postchallenge. Titers of neutralizing antibodies are the reciprocal plasma dilution at which 50% of CEMx174 cells were protected from virus-induced cell killing. Undetectable neutralization was given a value of 30, which was the lowest reciprocal plasma dilution tested. Panel A, MVA-gag-pol; panel B, MVA-env; panel C, MVA-gag-pol-env; panel D, MVA. †, animals sacrificed because of clinical manifestations of AIDS; ✞, animal that died of causes unrelated to AIDS.

Tables

  • Figures
  • Table 1.

    Magnitude and cross-reactivity of neutralizing antibodies detected 2 weeks post-virus challenge

    Vaccine group and animal no.aNab titer to SIV ofb:
    smH-4DeltaB670mac251
    MVA-SIV-gag-pol
     A4<30<20<20
     A542031<20
     A639630<20
    MVA-SIV-env
     B128,4782,11645
     B543,6805,947831
     B660,3093,48337
    MVA-SIV-gag-pol-env
     C150,0726,034969
     C542,2973,700958
     C648,9382,56148
    MVA
     D1<20<20<20
     D2<20<20<20
     D4<20<2044
    • ↵a Plasma samples from three animals in each of four immunization groups were obtained 2 weeks post-intravenous challenge with SIVsmE660.

    • ↵b Plasma samples were assessed for antibodies neutralizing SIVsmH-4, SIV/DeltaB670, and SIVmac251 in CEMx174 cells as described in the text. Titers of neutralizing antibodies are the reciprocal plasma dilution at which 50% of cells were protected from virus-induced killing.

  • Table 2.

    Magnitude and cross-reactivity of neutralizing antibodies detected 8 weeks post-virus challenge

    Vaccine group and animal no.aNab titer to SIV ofb:
    smH-4E660DeltaB670mac251mac239
    MVA-SIV-gag-pol
     A45,788<302,011476<20
     A55,539<301,978343<20
     A614,168<303,713503<20
    MVA-SIV-env
     B126,347<301,968162<20
     B511,279<301,599756<20
     B611,546<30506<20<20
    MVA-SIV-gag-pol-env
     C129,281<304,127858<20
     C516,3101802,9501,015<20
     C619,422<302,494<20<20
    MVA
     D110,633<304,689661<20
     D23,206<301,118345<20
     D47,405<302,465337<20
    • ↵a Plasma samples from three animals in each of four immunization groups were obtained 8 weeks post-intravenous challenge with SIVsmE660.

    • ↵b Plasma samples were assessed for antibodies neutralizing SIVsmH-4, SIVsmE660, SIV/DeltaB670, SIVmac251, and molecularly cloned SIVmac239 in CEMx174 cells as described in the text. Titers of neutralizing antibodies are the reciprocal plasma dilution at which 50% of cells were protected from virus-induced killing.

  • Table 3.

    Comparative neutralization of the assay and animal challenge stocks of SIVsmE660

    Animal no.aNab titer measured with SIVsmE660b:
    Cell viabilityReduction in p27
    Assay stockChallenge stockChallenge stock
    B51,0821,3402,118
    B61,8417,5027,405
    C1470384181
    • ↵a Plasma samples were obtained 28 weeks post-intravenous inoculation with SIVsmE660.

    • ↵b Neutralization was measured with the assay stock of SIVsmE660 grown in CEMx174 cells and the animal challenge stock of the same virus grown in macaque PBMC. Assays were performed with CEMx174 cells as described in the text with one modification: cells exposed to the animal challenge stock of virus were washed three times with growth medium 1 day after the addition of cells in order to remove the virus inoculum and residual anti-p27 antibodies. Culture supernatants were harvested for p27 quantification at the time cells were stained for viability. Neutralization titers are the reciprocal plasma dilution where either 50% of cells were protected from virus-induced killing or p27 synthesis was reduced 90% relative to virus control wells (no plasma sample). The average amount of p27 present in the virus control wells was 95 ng/ml.

PreviousNext
Back to top
Download PDF
Citation Tools
Recombinant Modified Vaccinia Virus Ankara Expressing the Surface gp120 of Simian Immunodeficiency Virus (SIV) Primes for a Rapid Neutralizing Antibody Response to SIV Infection in Macaques
Ilnour Ourmanov, Miroslawa Bilska, Vanessa M. Hirsch, David C. Montefiori
Journal of Virology Mar 2000, 74 (6) 2960-2965; DOI: 10.1128/JVI.74.6.2960-2965.2000

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Journal of Virology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Recombinant Modified Vaccinia Virus Ankara Expressing the Surface gp120 of Simian Immunodeficiency Virus (SIV) Primes for a Rapid Neutralizing Antibody Response to SIV Infection in Macaques
(Your Name) has forwarded a page to you from Journal of Virology
(Your Name) thought you would be interested in this article in Journal of Virology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Recombinant Modified Vaccinia Virus Ankara Expressing the Surface gp120 of Simian Immunodeficiency Virus (SIV) Primes for a Rapid Neutralizing Antibody Response to SIV Infection in Macaques
Ilnour Ourmanov, Miroslawa Bilska, Vanessa M. Hirsch, David C. Montefiori
Journal of Virology Mar 2000, 74 (6) 2960-2965; DOI: 10.1128/JVI.74.6.2960-2965.2000
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • ACKNOWLEDGMENTS
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

Antibodies, Viral
HIV Envelope Protein gp120
Membrane Glycoproteins
Simian Acquired Immunodeficiency Syndrome
Vaccines, DNA
Viral Envelope Proteins
Viral Vaccines

Related Articles

Cited By...

About

  • About JVI
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #Jvirology

@ASMicrobiology

       

 

JVI in collaboration with

American Society for Virology

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0022-538X; Online ISSN: 1098-5514